Sharman JP, Miranda P, Roos J, Emeribe U, et al. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia. Leuk Lymphoma 2023 May 23:1-10. doi: 10.1080/10428194.2023.2212433.
PMID: 37221877